Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.

Authors

Armstrong AJ, Saad F, Phung, Dmuchowski C, Shore ND, Fizazi K, Hirmand M, Forer D, Scher HI, Bono J.

Journal

Cancer

Year

2017

21st Century Oncology Physicians

Back
To top